Clinical Trials Browser

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Nausea, Neoplasms, Neuroblastoma, Sezary Syndrome, Testicular Neoplasms, Vomiting, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Phase 4 Completed

20 enrolled 5 charts

Gynecologic

Ovarian Neoplasms, Uterine Neoplasms, Vomiting

NCT02550119 2017-03-28

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Phase NA Terminated

19 enrolled

Gastrointestinal

Gastrointestinal Neoplasms, Nausea, Vomiting

NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

Phase 2 Completed

20 enrolled 8 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT01913990 2017-01-30

ER11-02

Phase 4 Unknown

323 enrolled

Nausea, Vomiting

NCT02979548 2017-01-25

Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy

Phase 3 Unknown

116 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02576327 2016-12-30

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

Phase 4 Unknown

130 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Vomiting, Hematologic Neoplasms

NCT00572572 2016-04-06

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Phase 3 Completed

69 enrolled 14 charts

Neoplasms, Germ Cell and Embryonal

NCT00293384 2016-03-15

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Phase NA Completed

40 enrolled 9 charts

BreastCNSDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Testicular Germ Cell Tumor, Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Nausea, Neuroblastoma, Ovarian Neoplasms, Sezary Syndrome, Testicular Neoplasms, Vomiting, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Gestational Trophoblastic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02445872 2015-12-09

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Phase 2 Unknown

80 enrolled

Thoracic

Lung Neoplasms, Nausea, Vomiting

NCT00475085 2015-11-10

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Phase 3 Completed

1,021 enrolled 10 charts

Breast

Breast Neoplasms, Nausea, Vomiting, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00954941 2015-06-25

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Phase 2 Completed

100 enrolled 7 charts

MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Nausea, Vomiting, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT02407600 2015-04-03

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Phase 2 Unknown

150 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Nausea, Vomiting

NCT02347878 2015-01-27

Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)

Phase 4 Unknown

85 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Post-Dural Puncture Headache

NCT01640340 2013-11-07

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Phase NA Completed

40 enrolled 12 charts

Tumor-Agnostic

Neoplasms

NCT00651755 2013-07-02

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Phase NA Completed

23 enrolled 14 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Nausea

NCT00314743 2013-05-24

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Phase EARLY_PHASE1 Completed

48 enrolled

Plasma cell

Multiple Myeloma, Nausea, Vomiting

NCT00869973 2013-01-23

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

Phase 3 Terminated

580 enrolled

Breast

Breast Neoplasms, Vomiting

NCT01012336 2012-10-10

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

Phase 2 Completed

89 enrolled 7 charts

Gynecologic

Ovarian Neoplasms, Vomiting

NCT01046461 2012-02-17

RAD

Phase 2 Unknown

41 enrolled

Nausea, Neoplasms, Vomiting, Postoperative Nausea and Vomiting

NCT00571168 2010-01-12

EmNa

Phase 3 Unknown

362 enrolled

Plasma cell

Multiple Myeloma, Vomiting

NCT00415103 2009-09-18

AMENO-2

Phase 4 Completed

196 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nausea, Vomiting

Clinical Trials

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

APHYPAP

Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

NRR

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.

CINV

Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis

Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

EGFR-TKIs

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

Efficacy of Aprepitant (Emend®) in Children

Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer

Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers

Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

HDIL2/Emend

RAPA

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Multi-day Doses in Prevention of Nausea and Emesis

ER11-02

Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation

Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients

Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin

RAD

EmNa

AMENO-2